Palbociclib slows cancer cell proliferation in patients with HR+/HER2- locally advanced or metastatic breast cancer.

A new study from Karolinska Institutet shows that gene analysis of breast cancer tumors can identify patients who do not ...

Please provide your email address to receive an email when new articles are posted on . Palbociclib plus endocrine therapy was not associated with lowered quality of life among Black, indigenous and ...

Researchers showed the potential of combining 2 precision medicines to overcome treatment resistance. When palbociclib, a breast cancer drug, and crizotinib, a lung cancer drug, were used in ...

Palbociclib plus endocrine therapy did not improve overall survival in premenopausal patients with metastatic breast cancer. The regimen did improve progression-free survival compared with ...

Female patient on hospital bed. Palbociclib added to adjuvant endocrine therapy failed to improve iDFS. The following article features coverage from the 2021 San Antonio Breast Cancer Symposium. Click ...

A recent trial sought to assess the effect of palbociclib on overall survival (OS) and the efficacy of subsequent therapy in patients with hormone receptor–positive (HR+), HER2-negative advanced ...

Please provide your email address to receive an email when new articles are posted on . The addition of palbociclib to anti-HER2 and endocrine therapy extended PFS by more than a year. The regimen ...

Credit: Getty Images. Continuing CDK4/6 inhibitor therapy and switching ET after disease progression does not improve progression-free survival vs switching ET alone in HR+, HER2- metastatic breast ...

A phase I/II study of blinatumomab in combination with pembrolizumab for adults with relapsed refractory B-lineage acute lymphoblastic leukemia: University of California Hematologic Malignancies ...

Palbociclib has been shown to be effective in treating metastatic breast cancer when used in combination with endocrine therapies. This study evaluated the effects of palbociclib plus letrozole as ...